HTG Molecular Diagnostics provides products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. Its qNPA™ molecular technology platform is designed to detect small changes in gene expression levels, including from formalin-fixed, paraffin-embedded (FFPE) tissue. The company offers a multi-plex gene expression testing platform and intends to use financing to increase adoption in molecular testing for translational medicine, pharmaceutical clinical development, and pathology laboratory diagnostics. HTG is led by CEO TJ Johnson and recently appointed John Lubniewski as chief business officer. The company staffs personnel with experience in sales and marketing, scientific R&D and operations. Financially, HTG has raised $16.2M in its Series D round to date, including a $500K second-tranche investment from SR One.

Total raised

$1M

Funding rounds

1

Latest round

Series D

Latest activity

Jun 2011